Abstract
Background Gaseous micro-embolism (GME) occurring during contemporary open heart surgery is poorly studied. Current understanding of the biological impact of cardiac surgery focuses on the surgical aggression itself together with contact activation of inflammatory cascades by the extracorporeal circulation (ECC), both promoting various degrees of a systemic inflammatory response syndrome (SIRS).
Methods and Findings We prospectively collected data on GME in the ECC circuit according to a quality control protocol during a 12-month period at our institution. Bubbles were measured means of a last generation multi-channel ultrasound measuring unit (BCC300, Gampt GmbH, Meerseburg, Germany) upstream of the arterial line filter. For analysis, bubbles were separated in three size categories: small (S) (10-40 µm), medium (M) (41-200 µm) and large (L) (201-2000 µm). Small bubbles were considered as noise and excluded. A total of 58 out of 70 open heart procedures were included in the final evaluation performed on 58 patients (45 males, 13 females, mean age 66 ± 9 years). Patient baseline data, type of procedure and perfusion data were retrieved. Preoperative treatment with beta-blockers, ACE-inhibitors, calcium-antagonists and statins was considered. Postoperative SIRS was identified according to modified SIRS and qSOFA criteria.
A variably high amount of GME was detected (mean count 847 ± 2560), we focused on M-sized GME (mean count 820 ± 2546, mean volume 233 ± 730 nL). A total of 22 patients (38%) developed SIRS. To account for differences between patient groups (SIRS-/ SIRS+) propensity score (PS) matching was performed on the presence of M-bubbles at or above the 75th percentile (count and volume). The impact of such GME on the development of SIRS was statistically highly significant, as shown by the corresponding average treatment effects (ATE).
Conclusions Significant GME was associated with postoperative SIRS after cardiac surgery in our setting. This novel finding warrants further confirmation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was partially funded by grant FF 20134 from the Swiss Heart Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee of Canton Ticino (Switzerland) approved the study (approval nr. CE TI 4029, dated January 20, 2022).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
